Advances in Therapeutic Cancer Vaccines

Advances in Immunology

Volumn 130, Issue , 2016, Pages 191-249

  Wong, Karrie K ^a   Li, WeiWei Aileen ^b,c   Mooney, David J ^b,c   Dranoff, Glenn ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Cancer antigens; Cancer immunotherapy; Cancer vaccine

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; GP100 PEPTIDE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; MESSENGER RNA; MONTANIDE ISA 51; NY ESO 1 PEPTIDE VACCINE; ONCOLYTIC VIRUS; PEPTIDE VACCINE; PEXASTIMOGENE DEVACIREPVEC; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN E6; RESIQUIMOD; RILIMOGENE GLAFOLIVEC; RNA VACCINE; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TECEMOTIDE; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; VITESPEN;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ALVEOLAR SOFT PART SARCOMA; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; BREAST TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LIVER CANCER; LOW DRUG DOSE; MELANOMA; MELANOMA B16; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS TUMOR; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CARCINOMA; SOLID TUMOR; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR REGRESSION; ACTIVE IMMUNOTHERAPY; ANIMAL; APOPTOSIS; BIOMEDICAL ENGINEERING; GENETICS; IMMUNOLOGY; MOUSE; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BIOMEDICAL ENGINEERING; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; NEOPLASMS; ONCOLYTIC VIRUSES; PERIPHERAL TOLERANCE;

EID: 84955324987     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/bs.ai.2015.12.001     Document Type: Chapter

References (336)

1. Abes R., Gelize E., Fridman W.H., Teillaud J.L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010, 116:926.
2. Agrawal B., Krantz M.J., Reddish M.A., Longenecker B.M. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. International Immunology 1998, 10:1907.
3. Ali O.A., Emerich D., Dranoff G., Mooney D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Science Translational Medicine 2009, 1:8ra19.
4. Ali O.A., Huebsch N., Cao L., Dranoff G., Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nature Materials 2009, 8:151.
5. Ali O.A., Verbeke C., Johnson C., Sands R.W., Lewin S.A., White D., et al. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Research 2014, 74:1670.
6. Amin A., Dudek A.Z., Logan T.F., Lance R.S., Holzbeierlein J.M., Knox J.J., et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal for Immunotherapy of Cancer 2015, 3:14.
7. Anandasabapathy N., Feder R., Mollah S., Tse S.W., Longhi M.P., Mehandru S. Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. The Journal of Experimental Medicine 2014, 211:1875.
8. Antonia S.J., Seigne J., Diaz J., Muro-Cacho C., Extermann M., Farmelo M.J. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. The Journal of Urology 2002, 167:1995.
9. Arlen P.M., Gulley J.L., Madan R.A., Hodge J.W., Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Critical Reviews in Immunology 2007, 27:451.
10. Atanackovic D., Altorki N.K., Cao Y., Ritter E., Ferrara C.A., Ritter G. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:1650.
11. Ayyoub M., Rimoldi D., Guillaume P., Romero P., Cerottini J.C., Valmori D., et al. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Research 2003, 63:5601.
12. Baitsch L., Baumgaertner P., Devevre E., Raghav S.K., Legat A., Barba L., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. The Journal of Clinical Investigation 2011, 121:2350.
13. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Research 2001, 61:6451.
14. Barker C.A., Postow M.A., Khan S.A., Beal K., Parhar P.K., Yamada Y., et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunology Research 2013, 1:92.
15. Bencherif S.A., Sands R.W., Bhatta D., Arany P., Verbeke C.S., Edwards D.A., et al. Injectable preformed scaffolds with shape-memory properties. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:19590.
16. Bencherif S.A., Warren Sands R., Ali O.A., Li W.A., Lewin S.A., Braschler T.M., et al. Injectable cryogel-based whole-cell cancer vaccines. Nature Communications 2015, 6:7556.
17. Benencia F., Courreges M.C., Conejo-Garcia J.R., Mohamed-Hadley A., Zhang L., Buckanovich R.J., et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Molecular Therapy 2005, 12:789.
18. Benencia F., Courreges M.C., Fraser N.W., Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biology & Therapy 2008, 7:1194.
19. Bhat R., Dempe S., Dinsart C., Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. International Journal of Cancer 2011, 128:908.
20. Bhat R., Rommelaere J. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer 2013, 13:367.
21. Billiau A., Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. Journal of Leukocyte Biology 2001, 70:849.
22. Bowne W.B., Wolchok J.D., Hawkins W.G., Srinivasan R., Gregor P., Blachere N.E., et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines, Cellular & Molecular Therapy 1999, 5:217.
23. Breitbach C.J., Arulanandam R., De Silva N., Thorne S.H., Patt R., Daneshmand M., et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Research 2013, 73:1265.
24. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99.
25. Brockstedt D.G., Giedlin M.A., Leong M.L., Bahjat K.S., Gao Y., Luckett W., et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:13832.
26. Brody J.D., Ai W.Z., Czerwinski D.K., Torchia J.A., Levy M., Advani R.H., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. Journal of Clinical Oncology 2010, 28:4324.
27. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. The Journal of Experimental Medicine 2013, 210:1685.
28. Burkhardt U.E., Hainz U., Stevenson K., Goldstein N.R., Pasek M., Naito M., et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. The Journal of Clinical Investigation 2013, 123:3756.
29. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulieres D., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. Journal of Clinical Oncology 2005, 23:6674.
30. Butts C., Socinski M.A., Mitchell P.L., Thatcher N., Havel L., Krzakowski M., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. The Lancet Oncology 2014, 15:59.
31. Califano J.A., Khan Z., Noonan K.A., Rudraraju L., Zhang Z., Wang H., et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clinical Cancer Research 2015, 21:30.
32. Campbell C.T., Gulley J.L., Oyelaran O., Hodge J.W., Schlom J., Gildersleeve J.C. Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proceedings of the National Academy of Sciences of the United States of America 2014, 111:E1749.
33. Capes J.S., Ando H.Y., Cameron R.E. Fabrication of polymeric scaffolds with a controlled distribution of pores. Journal of Materials Science. Materials in Medicine 2005, 16:1069.
34. Carreno B.M., Anderson R.W., Coligan J.E., Biddison W.E. LA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:3420.
35. Carreno B.M., Becker-Hapak M., Huang A., Chan M., Alyasiry A., Lie W.R., et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. The Journal of Clinical Investigation 2013, 123:3383.
36. Carreno B.M., Magrini V., Becker-Hapak M., Kaabinejadian S., Hundal J., Petti A.A., et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348:803.
37. Casey K.A., Mescher M.F. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. Journal of Immunology 2007, 178:7640.
38. Champiat S., Ferte C., Lebel-Binay S., Eggermont A., Soria J.C. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014, 3:e27817.
39. Chandra D., Quispe-Tintaya W., Jahangir A., Asafu-Adjei D., Ramos I., Sintim H.O., et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunology Research 2014, 2:901.
40. Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A., Gentles A.J., Volkmer J., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science Translational Medicine 2010, 2:63ra94.
41. Chao M.P., Weissman I.L., Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Current Opinion in Immunology 2012, 24:225.
42. Chen Y.T. Cancer vaccine: Identification of human tumor antigens by SEREX. The Cancer Journal 2000, 6(Suppl. 3):S208.
43. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9363.
44. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:1914.
45. Chiocca E.A. Oncolytic viruses. Nature Reviews. Cancer 2002, 2:938.
46. Chua B.Y., Sekiya T., Al Kobaisi M., Short K.R., Mainwaring D.E., Jackson D.C. A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year. Biomaterials 2015, 53:50.
47. Clancy-Thompson E., King L.K., Nunnley L.D., Mullins I.M., Slingluff C.L., Mullins D.W. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunology Research 2013, 1:332.
48. Colombo M.P., Ferrari G., Stoppacciaro A., Parenza M., Rodolfo M., Mavilio F. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. The Journal of Experimental Medicine 1991, 173:889.
49. Conry R.M., LoBuglio A.F., Wright M., Sumerel L., Pike M.J., Johanning F., et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Research 1995, 55:1397.
50. Coulie P.G., Brichard V., Van Pel A., Wolfel T., Schneider J., Traversari C., et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of Experimental Medicine 1994, 180:35.
51. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7976.
52. Coulie P.G., Van den Eynde B.J., van der Bruggen P., Boon T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nature Reviews. Cancer 2014, 14:135.
53. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994, 264:716.
54. Crocenzi T.S., Crittenden M., Wolf R., Hammill C., Newell P., Savoy A., et al. An exploratory phase I trial of immunochemoradiotherapy in locally advanced and borderline resectable (LA/BR) pancreatic adenocarcinoma (PC). Journal of Clinical Oncology 2013, 31. (abstr 174).
55. Cu Y., Booth C.J., Saltzman W.M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. Journal of Controlled Release 2011, 156:258.
56. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:4275.
57. Dannull J., Haley N.R., Archer G., Nair S., Boczkowski D., Harper M., et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. The Journal of Clinical Investigation 2013, 123:3135.
58. Davenport M.P., Smith K.J., Barouch D., Reid S.W., Bodnar W.M., Willis A.C., et al. HLA class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. The Journal of Experimental Medicine 1997, 185:367.
59. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10697.
60. Davis M.B., Vasquez-Dunddel D., Fu J., Albesiano E., Pardoll D., Kim Y.J. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clinical Cancer Research 2011, 17:3984.
61. Del Corno M., Michienzi A., Masotti A., Da Sacco L., Bottazzo G.F., Belardelli F., et al. CC chemokine ligand 2 down-modulation by selected Toll-like receptor agonist combinations contributes to T helper 1 polarization in human dendritic cells. Blood 2009, 114:796.
62. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27:3013.
63. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843.
64. Derre L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. The Journal of Clinical Investigation 2010, 120:157.
65. Dewan M.Z., Vanpouille-Box C., Kawashima N., DiNapoli S., Babb J.S., Formenti S.C., et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clinical Cancer Research 2012, 18:6668.
66. Dhodapkar M.V., Sznol M., Zhao B., Wang D., Carvajal R.D., Keohan M.L., et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Science Translational Medicine 2014, 6:232ra51.
67. Diaconu I., Cerullo V., Hirvinen M.L., Escutenaire S., Ugolini M., Pesonen S.K., et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Research 2012, 72:2327.
68. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529.
69. Diken M., Kreiter S., Vascotto F., Selmi A., Attig S., Diekmann J., et al. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunology Research 2013, 1:386.
70. DiLillo D.J., Ravetch J.V. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 2015, 161:1035.
71. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88:202.
72. Dominguez A.L., Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine 2010, 28:1383.
73. Dougan M., Dougan S., Slisz J., Firestone B., Vanneman M., Draganov D., et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. The Journal of Experimental Medicine 2010, 207:2195.
74. Dranoff G. GM-CSF-based cancer vaccines. Immunological Reviews 2002, 188:147.
75. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:3539.
76. Duan F., Duitama J., Al Seesi S., Ayres C.M., Corcelli S.A., Pawashe A.P., et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. The Journal of Experimental Medicine 2014, 211:2231.
77. Dubensky T.W., Reed S.G. Adjuvants for cancer vaccines. Seminars in Immunology 2010, 22:155.
78. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850.
79. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405.
80. Duraiswamy J., Kaluza K.M., Freeman G.J., Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Research 2013, 73:3591.
81. Ebert L.M., MacRaild S.E., Zanker D., Davis I.D., Cebon J., Chen W. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PloS One 2012, 7:e48424.
82. Eder J.P., Kantoff P.W., Roper K., Xu G.X., Bubley G.J., Boyden J., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research 2000, 6:1632.
83. Egilmez N.K., Jong Y.S., Hess S.D., Jacob J.S., Mathiowitz E., Bankert R.B. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model. Journal of Immunotherapy 2000, 23:190.
84. Enzler T., Gillessen S., Manis J.P., Ferguson D., Fleming J., Alt F.W., et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. The Journal of Experimental Medicine 2003, 197:1213.
85. Errington F., Steele L., Prestwich R., Harrington K.J., Pandha H.S., Vidal L., et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. Journal of Immunology 2008, 180:6018.
86. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351:290.
87. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. Journal of Immunology 2004, 173:3148.
88. Figdor C.G., van Kooyk Y., Adema G.J. C-type lectin receptors on dendritic cells and Langerhans cells. Nature Reviews. Immunology 2002, 2:77.
89. Flynn B.J., Kastenmuller K., Wille-Reece U., Tomaras G.D., Alam M., Lindsay R.W., et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7131.
90. Francois V., Ottaviani S., Renkvist N., Stockis J., Schuler G., Thielemans K., et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Research 2009, 69:4335.
91. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research 2013, 19:1225.
92. Frohlich A., Kisielow J., Schmitz I., Freigang S., Shamshiev A.T., Weber J., et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324:1576.
93. Fu J., Kanne D.B., Leong M., Glickman L.H., McWhirter S.M., Lemmens E., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Science Translational Medicine 2015, 7:283ra52.
94. Fulci G., Breymann L., Gianni D., Kurozomi K., Rhee S.S., Yu J., et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:12873.
95. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology 2013, 14:1014.
96. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11.
97. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine 2012, 366:883.
98. Goldberg J.M., Fisher D.E., Demetri G.D., Neuberg D., Allsop S.A., Fonseca C., et al. Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clinical Cancer Research 2015, 21:3178.
99. Golden E.B., Chhabra A., Chachoua A., Adams S., Donach M., Fenton-Kerimian M., et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial. The Lancet Oncology 2015, 16:795.
100. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunology Research 2013, 1:365.
101. Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nature Reviews. Immunology 2009, 9:353.
102. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577.
103. Guilliams M., Bruhns P., Saeys Y., Hammad H., Lambrecht B.N. The function of Fcgamma receptors in dendritic cells and macrophages. Nature Reviews. Immunology 2014, 14:94.
104. Gujar S.A., Pan D.A., Marcato P., Garant K.A., Lee P.W. Oncolytic virus-initiated protective immunity against prostate cancer. Molecular Therapy 2011, 19:797.
105. Hailemichael Y., Dai Z., Jaffarzad N., Ye Y., Medina M.A., Huang X.F., et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nature Medicine 2013, 19:465.
106. Hamad I., Christy Hunter A., Rutt K.J., Liu Z., Dai H., Moein Moghimi S. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Molecular Immunology 2008, 45:3797.
107. Hansen T.H., Bouvier M. MHC class I antigen presentation: Learning from viral evasion strategies. Nature Reviews. Immunology 2009, 9:503.
108. Hanson M.C., Crespo M.P., Abraham W., Moynihan K.D., Szeto G.L., Chen S.H., et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. The Journal of Clinical Investigation 2015, 125:2532.
109. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. The American Journal of Pathology 2000, 156:1363.
110. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. The Journal of Experimental Medicine 2001, 194:769.
111. Hayes M.P., Wang J., Norcross M.A. Regulation of interleukin-12 expression in human monocytes: Selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995, 86:646.
112. Heidenreich R., Jasny E., Kowalczyk A., Lutz J., Probst J., Baumhof P., et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. International Journal of Cancer 2015, 137:372.
113. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526.
114. Henderson T.M., Ladewig K., Haylock D.N., McLeanb K.M., O'Connor A.J. Cryogels for biomedical applications. Journal of Materials Chemistry B 2013, 1:2682.
115. Heo J., Reid T., Ruo L., Breitbach C.J., Rose S., Bloomston M., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Medicine 2013, 19:329.
116. Hess P.R., Boczkowski D., Nair S.K., Snyder D., Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunology, Immunotherapy 2006, 55:672.
117. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 2010, 28:7897.
118. Hodi F.S. Dendritic cell activating scaffold in melanoma 2012, (Clinicaltrials.gov).
119. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:3005.
120. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4712.
121. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363:711.
122. Hori Y., Winans A.M., Huang C.C., Horrigan E.M., Irvine D.J. Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 2008, 29:3671.
123. Hori Y., Winans A.M., Irvine D.J. Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. Acta Biomaterialia 2009, 5:969.
124. Houghton A.N., Guevara-Patino J.A. Immune recognition of self in immunity against cancer. The Journal of Clinical Investigation 2004, 114:468.
125. Hu Y., Atukorale P.U., Lu J.J., Moon J.J., Um S.H., Cho E.C., et al. Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. Biomacromolecules 2009, 10:756.
126. Huebsch N., Mooney D.J. Inspiration and application in the evolution of biomaterials. Nature 2009, 462:426.
127. Idoyaga J., Lubkin A., Fiorese C., Lahoud M.H., Caminschi I., Huang Y., et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:2384.
128. Infante J.R., Dees E.C., Olszanski A.J., Dhuria S.V., Sen S., Cameron S., et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2014, 32:3103.
129. Iwasaki-Arai J., Iwasaki H., Miyamoto T., Watanabe S., Akashi K. Enforced granulocyte/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion. The Journal of Experimental Medicine 2003, 197:1311.
130. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. Journal of Clinical Oncology 2001, 19:145.
131. Jandus C., Bioley G., Dojcinovic D., Derre L., Baitsch L., Wieckowski S., et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: Peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Research 2009, 69:8085.
132. Jewell C.M., Lopez S.C., Irvine D.J. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:15745.
133. Jinushi M., Hodi F.S., Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:9190.
134. Jinushi M., Nakazaki Y., Dougan M., Carrasco D.R., Mihm M., Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. The Journal of Clinical Investigation 2007, 117:1902.
135. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. The Journal of Experimental Medicine 2010, 207:1247.
136. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology 1997, 27:3135.
137. Joyce J.A., Fearon D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348:74.
138. Kalergis A.M., Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. The Journal of Experimental Medicine 2002, 195:1653.
139. Kanerva A., Nokisalmi P., Diaconu I., Koski A., Cerullo V., Liikanen I., et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clinical Cancer Research 2013, 19:2734.
140. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine 2010, 363:411.
141. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2010, 28:1099.
142. Karapanagiotou E.M., Roulstone V., Twigger K., Ball M., Tanay M., Nutting C., et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clinical Cancer Research 2012, 18:2080.
143. Karbach J., Gnjatic S., Bender A., Neumann A., Weidmann E., Yuan J., et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. International Journal of Cancer 2010, 126:909.
144. Kared H., Leforban B., Montandon R., Renand A., Layseca Espinosa E., Chatenoud L., et al. Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood 2008, 112:2575.
145. Kastenmuller K., Wille-Reece U., Lindsay R.W., Trager L.R., Darrah P.A., Flynn B.J., et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. The Journal of Clinical Investigation 2011, 121:1782.
146. Kaufman H.L., Kim D.W., DeRaffele G., Mitcham J., Coffin R.S., Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Annals of Surgical Oncology 2010, 17:718.
147. Kaufman H.L., Wang W., Manola J., DiPaola R.S., Ko Y.J., Sweeney C., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2004, 22:2122.
148. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. The Journal of Experimental Medicine 1994, 180:347.
149. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. The New England Journal of Medicine 2009, 361:1838.
150. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine 2000, 6:879.
151. Kim J., Bencherif S.A., Li W.A., Mooney D.J. Cell-friendly inverse opal-like hydrogels for a spatially separated co-culture system. Macromolecular Rapid Communications 2014, 35:1578.
152. Kim M.K., Breitbach C.J., Moon A., Heo J., Lee Y.K., Cho M., et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Science Translational Medicine 2013, 5:185ra63.
153. Kim J., Li W.A., Choi Y., Lewin S.A., Verbeke C.S., Dranoff G., et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nature Biotechnology 2015, 33:64.
154. Kim J., Mooney D.J. In vivo modulation of dendritic cells by engineered materials: Towards new cancer vaccines. Nano Today 2011, 6:466.
155. Klavinskis L.S., Barnfield C., Gao L., Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. Journal of Immunology 1999, 162:254.
156. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116:1685.
157. Klein O., Davis I.D., McArthur G.A., Chen L., Haydon A., Parente P., et al. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. Cancer Immunology, Immunotherapy 2015, 64:507.
158. Kloetzel P.M. Generation of major histocompatibility complex class I antigens: Functional interplay between proteasomes and TPPII. Nature Immunology 2004, 5:661.
159. Knight D.A., Ngiow S.F., Li M., Parmenter T., Mok S., Cass A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. The Journal of Clinical Investigation 2013, 123:1371.
160. Koks C.A., Garg A.D., Ehrhardt M., Riva M., Vandenberk L., Boon L., et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. International Journal of Cancer 2015, 136:E313.
161. Kortylewski M., Swiderski P., Herrmann A., Wang L., Kowolik C., Kujawski M., et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nature Biotechnology 2009, 27:925.
162. Koshy S.T., Ferrante T.C., Lewin S.A., Mooney D.J. Injectable, porous, and cell-responsive gelatin cryogels. Biomaterials 2014, 35:2477.
163. Kourtis I.C., Hirosue S., de Titta A., Kontos S., Stegmann T., Hubbell J.A. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PloS One 2013, 8:e61646.
164. Kreiter S., Diken M., Selmi A., Diekmann J., Attig S., Husemann Y., et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Research 2011, 71:6132.
165. Kreiter S., Selmi A., Diken M., Koslowski M., Britten C.M., Huber C., et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Research 2010, 70:9031.
166. Kreiter S., Vormehr M., van de Roemer N., Diken M., Lower M., Diekmann J., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015, 520:692.
167. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nature Immunology 2005, 6:1219.
168. Kruit W.H., Suciu S., Dreno B., Mortier L., Robert C., Chiarion-Sileni V., et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of Clinical Oncology 2013, 31:2413.
169. Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nature Reviews. Cancer 2012, 12:860.
170. Kuksa P.P., Min M.R., Dugar R., Gerstein M. High-order neural networks and kernel methods for peptide-MHC binding prediction. Bioinformatics 2015, 31(22):3600-3607.
171. Kumamoto T., Huang E.K., Paek H.J., Morita A., Matsue H., Valentini R.F., et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nature Biotechnology 2002, 20:64.
172. Kwong B., Gai S.A., Elkhader J., Wittrup K.D., Irvine D.J. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Research 2013, 73:1547.
173. Kwong B., Liu H., Irvine D.J. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials 2011, 32:5134.
174. Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:261.
175. Le D.T., Brockstedt D.G., Nir-Paz R., Hampl J., Mathur S., Nemunaitis J., et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clinical Cancer Research 2012, 18:858.
176. Le D.T., Lutz E., Uram J.N., Sugar E.A., Onners B., Solt S., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of Immunotherapy 2013, 36:382.
177. Leone P., Shin E.C., Perosa F., Vacca A., Dammacco F., Racanelli V. MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells. Journal of the National Cancer Institute 2013, 105:1172.
178. Li H., Li Y., Jiao J., Hu H.M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nature Nanotechnology 2011, 6:645.
179. Li A.V., Moon J.J., Abraham W., Suh H., Elkhader J., Seidman M.A., et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Science Translational Medicine 2013, 5:204ra130.
180. Li W.A., Mooney D.J. Materials based tumor immunotherapy vaccines. Current Opinion in Immunology 2013, 25:238.
181. Li B., VanRoey M., Wang C., Chen T.H., Korman A., Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clinical Cancer Research 2009, 15:1623.
182. Liang S.C., Moskalenko M., Van Roey M., Jooss K. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clinical Immunology 2013, 148:287.
183. Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nature Reviews. Cancer 2014, 14:559.
184. Linnemann C., van Buuren M.M., Bies L., Verdegaal E.M., Schotte R., Calis J.J., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature Medicine 2015, 21:81.
185. Lipson E.J., Sharfman W.H., Chen S., McMiller T.L., Pritchard T.S., Salas J.T., et al. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. Journal of Translational Medicine 2015, 13:214.
186. Liu H., Moynihan K.D., Zheng Y., Szeto G.L., Li A.V., Huang B., et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014, 507:519.
187. Lu Y.C., Yao X., Li Y.F., El-Gamil M., Dudley M.E., Yang J.C., et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. Journal of Immunology 2013, 190:6034.
188. Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.A., et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: Prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002, 100:1362.
189. Lutz E.R., Wu A.A., Bigelow E., Sharma R., Mo G., Soares K., et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunology Research 2014, 2:616.
190. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Research 2000, 60:3239.
191. Madan R.A., Aragon-Ching J.B., Gulley J.L., Dahut W.L. From clinical trials to clinical practice: Therapeutic cancer vaccines for the treatment of prostate cancer. Expert Review of Vaccines 2011, 10:743.
192. Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. The Journal of Cell Biology 2000, 151:673.
193. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C.M., Kapsenberg M.L., et al. alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Research 2004, 64:5934.
194. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. European Journal of Immunology 2008, 38:1404.
195. Maryanski J.L., Romero P., Van Pel A., Boon T., Salemme F.R., Cerottini J.C., et al. The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. International Immunology 1991, 3:1035.
196. Matsuo K., Koizumi H., Akashi M., Nakagawa S., Fujita T., Yamamoto A., et al. Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. Journal of Controlled Release 2011, 152:310.
197. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400.
198. Mehta N.K., Moynihan K.D., Irvine D.J. Engineering new approaches to cancer vaccines. Cancer Immunology Research 2015, 3:836.
199. Meixlsperger S., Leung C.S., Ramer P.C., Pack M., Vanoaica L.D., Breton G., et al. CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013, 121:5034.
200. Mellman I., Steinman R.M. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001, 106:255.
201. Michael A., Ball G., Quatan N., Wushishi F., Russell N., Whelan J., et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clinical Cancer Research 2005, 11:4469.
202. Mildner A., Jung S. Development and function of dendritic cell subsets. Immunity 2014, 40:642.
203. Milne P., Bigley V., Gunawan M., Haniffa M., Collin M. CD1c+ blood dendritic cells have Langerhans cell potential. Blood 2015, 125:470.
204. Mitchell D.A., Batich K.A., Gunn M.D., Huang M.N., Sanchez-Perez L., Nair S.K., et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015, 519:366.
205. Moehler M., Sieben M., Roth S., Springsguth F., Leuchs B., Zeidler M., et al. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer 2011, 11:464.
206. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:1080.
207. Moon J.J., Suh H., Polhemus M.E., Ockenhouse C.F., Yadava A., Irvine D.J. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PloS One 2012, 7:e31472.
208. Morishige T., Yoshioka Y., Inakura H., Tanabe A., Yao X., Narimatsu S., et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. Biomaterials 2010, 31:6833.
209. Mosca P.J., Hobeika A.C., Clay T.M., Nair S.K., Thomas E.K., Morse M.A. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 2000, 96:3499.
210. Narusawa M., Inoue H., Sakamoto C., Matsumura Y., Takahashi A., Inoue T., et al. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Cancer Immunology Research 2014, 2:568.
211. Nehoff H., Parayath N.N., Domanovitch L., Taurin S., Greish K. Nanomedicine for drug targeting: Strategies beyond the enhanced permeability and retention effect. International Journal of Nanomedicine 2014, 9:2539.
212. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:E989.
213. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 1998, 4:328.
214. Nicholaou T., Ebert L.M., Davis I.D., McArthur G.A., Jackson H., Dimopoulos N., et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research 2009, 15:2166.
215. Nizzoli G., Krietsch J., Weick A., Steinfelder S., Facciotti F., Gruarin P., et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013, 122:932.
216. Nochi T., Yuki Y., Takahashi H., Sawada S., Mejima M., Kohda T., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nature Materials 2010, 9:572.
217. Noonan K.A., Ghosh N., Rudraraju L., Bui M., Borrello I. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunology Research 2014, 2:725.
218. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine 2007, 13:54.
219. Odunsi K., Qian F., Matsuzaki J., Mhawech-Fauceglia P., Andrews C., Hoffman E.W., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12837.
220. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with (alpha)-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Journal of Clinical Oncology 2011, 29:330.
221. Pan P.Y., Wang G.X., Yin B., Ozao J., Ku T., Divino C.M., et al. Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111:219.
222. Park S.S., Dong H., Liu X., Harrington S.M., Krco C.J., Grams M.P., et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunology Research 2015, 3:610.
223. Park J., Gao W., Whiston R., Strom T.B., Metcalfe S., Fahmy T.M. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Molecular Pharmaceutics 2011, 8:143.
224. Park J., Wrzesinski S.H., Stern E., Look M., Criscione J., Ragheb R., et al. Combination delivery of TGF-beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nature Materials 2012, 11:895.
225. Pearce E.L., Shen H. Generation of CD8 T cell memory is regulated by IL-12. Journal of Immunology 2007, 179:2074.
226. Peters B., Tong W., Sidney J., Sette A., Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics 2003, 19:1765.
227. Piesche M., Ho V.T., Kim H., Nakazaki Y., Nehil M., Yaghi N.K., et al. Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clinical Cancer Research 2015, 21:1010.
228. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine 2012, 366:925.
229. Prestwich R.J., Errington F., Ilett E.J., Morgan R.S., Scott K.J., Kottke T., et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clinical Cancer Research 2008, 14:7358.
230. Prestwich R.J., Ilett E.J., Errington F., Diaz R.M., Steele L.P., Kottke T. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clinical Cancer Research 2009, 15:4374.
231. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: Combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461.
232. Probst J., Weide B., Scheel B., Pichler B.J., Hoerr I., Rammensee H.G., et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Therapy 2007, 14:1175.
233. Qin H., Lerman B., Sakamaki I., Wei G., Cha S.C., Rao S.S., et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine 2014, 20:676.
234. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation 2006, 116:1935.
235. Rajasagi M., Shukla S.A., Fritsch E.F., Keskin D.B., DeLuca D., Carmona E., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124:453.
236. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213.
237. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. Journal of Controlled Release 2006, 112:26.
238. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology 2007, 25:1159.
239. Rittig S.M., Haentschel M., Weimer K.J., Heine A., Muller M.R., Brugger W., et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Molecular Therapy 2011, 19:990.
240. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124.
241. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine 2013, 19:747.
242. Rooney M.S., Shukla S.A., Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160:48.
243. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. The New England Journal of Medicine 1988, 319:1676.
244. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine 1998, 4:321.
245. Sabado R.L., Pavlick A., Gnjatic S., Cruz C.M., Vengco I., Hasan F., et al. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunology Research 2015, 3:278.
246. Sahin U., Kariko K., Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nature Reviews. Drug Discovery 2014, 13:759.
247. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:11810.
248. Salazar A.M., Erlich R.B., Mark A., Bhardwaj N., Herberman R.B. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: Case report, hypothesis, and clinical trial. Cancer Immunology Research 2014, 2:720.
249. Salgaller M.L., Marincola F.M., Cormier J.N., Rosenberg S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Research 1996, 56:4749.
250. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. Journal of Clinical Oncology 2003, 21:624.
251. Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martinez D., Hernanz-Falcon P., et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899.
252. Sandler A.D., Chihara H., Kobayashi G., Zhu X., Miller M.A., Scott D.L., et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Research 2003, 63:394.
253. Sano K., Nakajima T., Choyke P.L., Kobayashi H. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 2013, 7:717.
254. Santegoets S.J., Stam A.G., Lougheed S.M., Gall H., Jooss K., Sacks N., et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. Journal for Immunotherapy of Cancer 2014, 2:31.
255. Schellhammer P.F., Chodak G., Whitmore J.B., Sims R., Frohlich M.W., Kantoff P.W. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013, 81:1297.
256. Schmollinger J.C., Vonderheide R.H., Hoar K.M., Maecker B., Schultze J.L., Hodi F.S., et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:3398.
257. Schoenfeld J., Jinushi M., Nakazaki Y., Wiener D., Park J., Soiffer R., et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Research 2010, 70:10150.
258. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565.
259. Schumacher T., Bunse L., Pusch S., Sahm F., Wiestler B., Quandt J., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, 512:324.
260. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England Journal of Medicine 2011, 364:2119.
261. Scott E.A., Stano A., Gillard M., Maio-Liu A.C., Swartz M.A., Hubbell J.A. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 2012, 33:6211.
262. Segura E., Valladeau-Guilemond J., Donnadieu M.H., Sastre-Garau X., Soumelis V., Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. The Journal of Experimental Medicine 2012, 209:653.
263. Selbo P.K., Weyergang A., Hogset A., Norum O.J., Berstad M.B., Vikdal M., et al. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. Journal of Controlled Release 2010, 148:2.
264. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunology Research 2013, 1:32.
265. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research 2004, 64:6337.
266. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. The Journal of Experimental Medicine 2006, 203:2691.
267. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006, 117:78.
268. Sikora A.G., Jaffarzad N., Hailemichael Y., Gelbard A., Stonier S.W., Schluns K.S., et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. Journal of Immunology 2009, 182:7398.
269. Simons J.W., Jaffee E.M., Weber C.E., Levitsky H.I., Nelson W.G., Carducci M.A., et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Research 1997, 57:1537.
270. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., et al. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Research 1999, 59:5160.
271. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of Experimental Medicine 2013, 210:1695.
272. Singh P., Pal S.K., Alex A., Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncology 2015, 11:2137.
273. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine 2014, 20:1301.
274. Small E.J., Sacks N., Nemunaitis J., Urba W.J., Dula E., Centeno A.S., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clinical Cancer Research 2007, 13:3883.
275. Soares K.C., Rucki A.A., Wu A.A., Olino K., Xiao Q., Chai Y., et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. Journal of Immunotherapy 2015, 38:1.
276. Soiffer R., Hodi F.S., Haluska F., Jung K., Gillessen S., Singer S., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. Journal of Clinical Oncology 2003, 21:3343.
277. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:13141.
278. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16:96.
279. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. The Journal of Clinical Investigation 2005, 115:739.
280. St John A.L., Chan C.Y., Staats H.F., Leong K.W., Abraham S.N. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nature Materials 2012, 11:250.
281. Stano A., Scott E.A., Dane K.Y., Swartz M.A., Hubbell J.A. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Biomaterials 2013, 34:4339.
282. Stanos S.P., Bruckenthal P., Barkin R.L. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: Potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proceedings 2012, 87:683.
283. Starbeck-Miller G.R., Xue H.H., Harty J.T. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. The Journal of Experimental Medicine 2014, 211:105.
284. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annual Review of Immunology 2003, 21:685.
285. Stylianou E., Diogo G.R., Pepponi I., van Dolleweerd C., Arias M.A., Locht C., et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. European Journal of Immunology 2014, 44:440.
286. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27:4388.
287. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nature Reviews. Cancer 2013, 13:739.
288. Tamura Y., Peng P., Liu K., Daou M., Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278:117.
289. Testori A., Richards J., Whitman E., Mann G.B., Lutzky J., Camacho L., et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. Journal of Clinical Oncology 2008, 26:955.
290. Thomas D.L., Fraser N.W. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Molecular Therapy 2003, 8:543.
291. Thomas A.M., Santarsiero L.M., Lutz E.R., Armstrong T.D., Chen Y.C., Huang L.Q., et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. The Journal of Experimental Medicine 2004, 200:297.
292. Thomas S.N., Vokali E., Lund A.W., Hubbell J.A., Swartz M.A. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 2014, 35:814.
293. Toda M., Martuza R.L., Rabkin S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Molecular Therapy 2000, 2:324.
294. Todo T., Rabkin S.D., Sundaresan P., Wu A., Meehan K.R., Herscowitz H.B., et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Human Gene Therapy 1999, 10:2741.
295. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641.
296. Tseng D., Volkmer J.P., Willingham S.B., Contreras-Trujillo H., Fathman J.W., Fernhoff N.B., et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:11103.
297. Tsuji T., Sabbatini P., Jungbluth A.A., Ritter E., Pan L., Ritter G., et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunology Research 2013, 1:340.
298. Twyman-Saint Victor C., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373.
299. Ueno H., Schmitt N., Klechevsky E., Pedroza-Gonzalez A., Matsui T., Zurawski G., et al. Harnessing human dendritic cell subsets for medicine. Immunological Reviews 2010, 234:199.
300. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F.F., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. Journal of Clinical Oncology 2013, 31:2388.
301. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8947.
302. van den Eertwegh A.J., Versluis J., van den Berg H.P., Santegoets S.J., van Moorselaar R.J., van der Sluis T.M., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. The Lancet Oncology 2012, 13:509.
303. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643.
304. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. The Journal of Experimental Medicine 1999, 190:355.
305. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. Journal of Clinical Oncology 2013, 31:e439.
306. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews. Cancer 2012, 12:237.
307. Vanpouille-Box C., Diamond J.M., Pilones K.A., Zavadil J., Babb J.S., Formenti S.C., et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Research 2015, 75:2232.
308. Vanpouille-Box C., Pilones K.A., Wennerberg E., Formenti S.C., Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015, 33:7415.
309. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. Journal of Clinical Oncology 2013, 31:2396.
310. Vansteenkiste J.F., Cho B., Vanakesa T., et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjunct therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Annals of Oncology 2014, 25(Suppl. 4):iv409-iv416. 10.1093/annonc/mdu347.
311. Velluto D., Thomas S.N., Simeoni E., Swartz M.A., Hubbell J.A. PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: Tumor immunotoxicity in B16F10 melanoma. Biomaterials 2011, 32:9839.
312. Verbeke C.S., Mooney D.J. Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells. Advanced Healthcare Materials 2015, 4:2677-2687.
313. Viatte S., Alves P.M., Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. Immunology and Cell Biology 2006, 84:318.
314. Vose B.M., Bonnard G.D. Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells. Nature 1982, 296:359.
315. Vose B.M., Bonnard G.D. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2. International Journal of Cancer 1982, 29:33.
316. Wada S., Yoshimura K., Hipkiss E.L., Harris T.J., Yen H.R., Goldberg M.V., et al. Cyclophosphamide augments antitumor immunity: Studies in an autochthonous prostate cancer model. Cancer Research 2009, 69:4309.
317. Wallecha A., Maciag P.C., Rivera S., Paterson Y., Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clinical and Vaccine Immunology 2009, 16:96.
318. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine 2012, 18:1254.
319. Weed D.T., Vella J.L., Reis I.M., De la Fuente A.C., Gomez C., Sargi Z., et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clinical Cancer Research 2015, 21:39.
320. Weide B., Carralot J.P., Reese A., Scheel B., Eigentler T.K., Hoerr I., et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy 2008, 31:180.
321. Weide B., Pascolo S., Scheel B., Derhovanessian E., Pflugfelder A., Eigentler T.K., et al. Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of Immunotherapy 2009, 32:498.
322. Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Research 2002, 62:5818.
323. Whitmire J.K., Tan J.T., Whitton J.L. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. The Journal of Experimental Medicine 2005, 201:1053.
324. Wick D.A., Webb J.R., Nielsen J.S., Martin S.D., Kroeger D.R., Milne K., et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clinical Cancer Research 2014, 20:1125.
325. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine 2013, 369:122.
326. Wood C.G., Mulders P. Vitespen: A preclinical and clinical review. Future Oncology 2009, 5:763.
327. Workenhe S.T., Pol J.G., Lichty B.D., Cummings D.T., Mossman K.L. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunology Research 2013, 1:309.
328. Yadav M., Jhunjhunwala S., Phung Q.T., Lupardus P., Tanguay J., Bumbaca S., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515:572.
329. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 2009, 360:765.
330. Yang S., Vervaert C.E., Burch J., Grichnik J., Seigler H.F., Darrow T.L. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. International Journal of Cancer 1999, 83:532.
331. Yu C.I., Becker C., Wang Y., Marches F., Helft J., Leboeuf M., et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity 2013, 38:818.
332. Zamarin D., Holmgaard R.B., Subudhi S.K., Park J.S., Mansour M., Palese P., et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine 2014, 6:226ra32.
333. Zarei S., Schwenter F., Luy P., Aurrand-Lions M., Morel P., Kopf M., et al. Role of GM-CSF signaling in cell-based tumor immunization. Blood 2009, 113:6658.
334. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. The Journal of Experimental Medicine 2005, 201:139.
335. Zhu Q., Talton J., Zhang G., Cunningham T., Wang Z., Waters R.C., et al. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nature Medicine 2012, 18:1291.
336. Zom G.G., Khan S., Britten C.M., Sommandas V., Camps M.G., Loof N.M., et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunology Research 2014, 2:756.